Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$16.26
+0.4%
$19.89
$13.22
$45.37
$932.11M-1.89872,055 shs785,636 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$630.55
-1.6%
$776.36
$623.78
$972.53
$597.66B0.444.00 million shs9.60 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$51.01
+4.6%
$67.55
$45.05
$139.74
$227.68B0.6311.30 million shs18.77 million shs
Roche Holding AG stock logo
RHHBY
Roche
$38.06
-1.5%
$40.33
$34.10
$44.31
$242.18B0.462.34 million shs867,631 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-0.67%-8.99%-13.55%-36.62%-52.39%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-14.21%-13.45%-17.71%-13.05%-17.09%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+7.62%+3.71%-29.97%-25.83%-59.15%
Roche Holding AG stock logo
RHHBY
Roche
+0.68%-0.75%-3.67%+0.65%-2.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
1.8708 of 5 stars
3.51.00.00.01.61.70.6
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9741 of 5 stars
4.34.03.34.03.81.71.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.3181 of 5 stars
3.05.03.30.03.00.03.1
Roche Holding AG stock logo
RHHBY
Roche
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
3.00
Buy$75.71365.65% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.68
Moderate Buy$999.5058.51% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.00
Hold$93.6783.62% Upside
Roche Holding AG stock logo
RHHBY
Roche
2.57
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest LLY, NVO, GPCR, and RHHBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$75.00 ➝ $60.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$92.00 ➝ $90.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$89.00 ➝ $87.00
8/7/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/7/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$715.00
8/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
7/31/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/31/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$57.00
7/30/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight
7/11/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$936.00 ➝ $942.00
7/10/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$1,133.00 ➝ $1,135.00
(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$15.10 per shareN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$49.00B12.20$12.03 per share52.43$15.03 per share41.95
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.12B5.41$4.39 per share11.63$4.66 per share10.95
Roche Holding AG stock logo
RHHBY
Roche
$68.73B3.52$3.28 per share11.61$6.46 per share5.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$122.53M-$1.05N/AN/AN/AN/A-20.76%-19.86%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2951.3120.261.0622.67%85.51%15.74%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.6414.0110.951.3735.60%84.92%25.29%N/A
Roche Holding AG stock logo
RHHBY
Roche
$9.40BN/A0.0012.692.98N/AN/AN/AN/A

Latest LLY, NVO, GPCR, and RHHBY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.28N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/6/2025Q2 2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.28-$0.36-$0.08-$0.36N/AN/A
8/6/2025Q2 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion
5/8/2025Q1 2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.24-$0.27-$0.03-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.95%N/A48.82%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.643.21%N/A45.05%N/A
Roche Holding AG stock logo
RHHBY
Roche
$0.872.29%N/AN/AN/A

Latest LLY, NVO, GPCR, and RHHBY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
8/7/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.41192.4%8/18/20258/18/20258/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
23.29
23.29
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.70
0.74
0.56
Roche Holding AG stock logo
RHHBY
Roche
0.85
1.48
1.20

Institutional Ownership

CompanyInstitutional Ownership
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Insider Ownership

CompanyInsider Ownership
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
9.43%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Roche Holding AG stock logo
RHHBY
Roche
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13657.34 million51.94 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.50 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
77,3494.47 billion4.46 billionOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,2496.36 billionN/ANot Optionable

Recent News About These Companies

Reviewing Sanofi (NASDAQ:SNY) and Roche (OTCMKTS:RHHBY)
Analyst Report: Roche Holding AG
Roche Reports Strong Half-Year Growth in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$16.26 +0.06 (+0.37%)
As of 02:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$630.39 -10.47 (-1.63%)
As of 02:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$51.01 +2.25 (+4.61%)
As of 02:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Roche stock logo

Roche OTCMKTS:RHHBY

$38.06 -0.56 (-1.45%)
As of 02:03 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.